AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$IQV

Berkshire James G. sold $697K of IQV

Berkshire James G. (See Remarks) sold 2,668 shares of IQVIA HOLDINGS INC. (IQV) at $261.33 ($0.70M total) on 2026-09-02.

Original reporting
SEC EDGAR · Berkshire James G.
Published Sep 4, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IQV
Bearish
medium confidence
Mentioned
$IQV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary source.

02

Market read

Small insider sale; limited trading impact but worth noting for short-term sentiment.

03

What to watch

No disclosed 10b5‑1 plan; insider may have personal liquidity needs.

Relevance 5/10Novelty 4/10Timing: filed Sep 4, 2026

Background

Form 4 filings disclose insider transactions; traders monitor them for sentiment cues.

Company-level read

Ticker impact

$IQVBearishMedium confidence
Context

Officer James G. Berkshire sold 2,668 shares of IQVIA for $697,228, reducing his stake to 10,890 shares.

Expected impact

Modest downward pressure; price may dip 1‑2% in the next trading session.

Evidence & confidence

Sale size is modest relative to market cap, but insider sales often attract short-term traders.

Market effects

Sector

Minimal impact on healthcare data analytics sector.

Regional

U.S. market only.

Global

Low

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    IQVIA Holdings Inc.

    Provider of health information technology and data analytics.

  • Officer
    James G. Berkshire

    Company officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IQV insider trading history →

Related articles

OCT 14
$IQVMed

Stifel raises IQVIA stock price target on improving market backdrop

Stifel raised its price target for IQVIA (NYSE:IQV) to $303 from $276, citing an improving market backdrop and strong company performance. The stock is near its 52-week high and has surged 48.72% over the past six months. Multiple analysts have raised their price targets and maintained buy ratings, highlighting IQVIA's growth prospects and strong data infrastructure.

investing.com1 min
SEP 19
$IQVHighAI 8/10

IQVIA Holdings (IQV) Prices $2b In Senior Notes, Is The Stock Still Undervalued?

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

simplywall.st2 min
SEP 17
$IQVMed

Learn Why The Bull Case For IQVIA (IQV) Could Change Following AI Trial Platform Launch

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.

simplywall.st3 min